REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 24, 2014--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical
company, today announced its intention to offer and sell shares of its
common stock in an underwritten offering pursuant to its existing shelf
registration. All of the shares in the proposed offering are to be sold
by Heron Therapeutics, Inc.
Jefferies LLC and Leerink Partners LLC are acting as joint book-runners
for the offering. Heron Therapeutics, Inc. intends to grant the
underwriters a 30-day option to purchase additional shares of its common
stock. The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or the
actual size or terms of the offering.
Heron Therapeutics, Inc. intends to use the net proceeds from the
underwritten offering for general corporate purposes, funding ongoing
and future clinical trials and for general and administrative expenses.
The securities described above are being offered pursuant to a shelf
registration statement (File No. 333-195928), which was declared
effective by the United States Securities and Exchange Commission
(“SEC”) on May 23, 2014. The securities described above have not been
qualified under any state blue sky laws. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any state
or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities
laws of any such state or other jurisdiction. The offering can be made
only by means of a prospectus, copies of which may be obtained at the
SEC’s website at www.sec.gov,
or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th Floor, New York, NY 10022,
telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com.
Source: Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
Investor Relations Contact:
Sr. Manager, Investor Relations
Brian Drazba, 650-366-2626
Vice President, Finance
and Chief Financial Officer